Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunoglobulin G | 22 | 2024 | 4549 | 1.860 |
Why?
|
| Plasma Cells | 4 | 2023 | 599 | 1.230 |
Why?
|
| Autoimmune Diseases | 7 | 2023 | 2247 | 1.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 8 | 2022 | 4369 | 0.910 |
Why?
|
| T-Lymphocytes, Cytotoxic | 6 | 2022 | 1766 | 0.720 |
Why?
|
| Autoantibodies | 4 | 2021 | 2123 | 0.640 |
Why?
|
| Fibrosis | 10 | 2024 | 2048 | 0.630 |
Why?
|
| Autoantigens | 3 | 2021 | 876 | 0.610 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2017 | 99 | 0.550 |
Why?
|
| Galectin 3 | 1 | 2018 | 240 | 0.540 |
Why?
|
| Th2 Cells | 2 | 2020 | 1054 | 0.520 |
Why?
|
| Dyspnea | 1 | 2023 | 1344 | 0.490 |
Why?
|
| Immunity, Humoral | 1 | 2017 | 604 | 0.420 |
Why?
|
| Rheumatology | 2 | 2019 | 615 | 0.410 |
Why?
|
| Vascular Diseases | 2 | 2016 | 1161 | 0.370 |
Why?
|
| Glucocorticoids | 6 | 2022 | 2163 | 0.360 |
Why?
|
| Antigens, CD | 1 | 2020 | 4000 | 0.330 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2020 | 1636 | 0.330 |
Why?
|
| Retroperitoneal Fibrosis | 2 | 2019 | 42 | 0.310 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 2805 | 0.310 |
Why?
|
| B-Lymphocytes | 4 | 2023 | 4748 | 0.290 |
Why?
|
| Apoptosis | 2 | 2020 | 9468 | 0.290 |
Why?
|
| Scleroderma, Systemic | 2 | 2021 | 344 | 0.270 |
Why?
|
| Immunologic Factors | 3 | 2018 | 1588 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2018 | 3439 | 0.210 |
Why?
|
| Pancreas | 2 | 2020 | 1684 | 0.210 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2023 | 239 | 0.200 |
Why?
|
| Hereditary Autoinflammatory Diseases | 1 | 2022 | 42 | 0.190 |
Why?
|
| Mediastinitis | 1 | 2020 | 49 | 0.180 |
Why?
|
| Histoplasma | 1 | 2020 | 39 | 0.180 |
Why?
|
| Arteritis | 1 | 2023 | 159 | 0.180 |
Why?
|
| Sjogren's Syndrome | 1 | 2022 | 234 | 0.180 |
Why?
|
| Histoplasmosis | 1 | 2020 | 63 | 0.180 |
Why?
|
| Immunotherapy | 1 | 2016 | 4649 | 0.180 |
Why?
|
| Humans | 47 | 2024 | 760437 | 0.180 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 13616 | 0.180 |
Why?
|
| Antigens, CD19 | 1 | 2023 | 425 | 0.180 |
Why?
|
| Sclerosis | 1 | 2020 | 210 | 0.180 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2021 | 262 | 0.170 |
Why?
|
| Fibroblasts | 2 | 2020 | 4106 | 0.170 |
Why?
|
| Receptors, Phospholipase A2 | 1 | 2019 | 33 | 0.160 |
Why?
|
| Mikulicz' Disease | 1 | 2019 | 8 | 0.160 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2020 | 225 | 0.160 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2019 | 427 | 0.160 |
Why?
|
| Vasculitis | 1 | 2023 | 522 | 0.160 |
Why?
|
| Pleural Effusion | 1 | 2022 | 342 | 0.160 |
Why?
|
| Immunosorbent Techniques | 1 | 2018 | 176 | 0.150 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2019 | 88 | 0.150 |
Why?
|
| Aortitis | 1 | 2019 | 74 | 0.150 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2019 | 97 | 0.150 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2022 | 386 | 0.150 |
Why?
|
| Digestive System Diseases | 1 | 2019 | 151 | 0.140 |
Why?
|
| Immunoglobulin E | 2 | 2022 | 1494 | 0.130 |
Why?
|
| Hereditary Central Nervous System Demyelinating Diseases | 1 | 2016 | 42 | 0.130 |
Why?
|
| Male | 26 | 2024 | 360035 | 0.130 |
Why?
|
| Lymphocyte Depletion | 1 | 2017 | 602 | 0.130 |
Why?
|
| Diagnosis, Differential | 4 | 2024 | 12969 | 0.120 |
Why?
|
| Rheumatic Diseases | 1 | 2022 | 648 | 0.120 |
Why?
|
| Immunoglobulins | 1 | 2018 | 859 | 0.120 |
Why?
|
| Exodeoxyribonucleases | 1 | 2016 | 192 | 0.120 |
Why?
|
| Early Diagnosis | 1 | 2019 | 1183 | 0.120 |
Why?
|
| Lymphocyte Activation | 3 | 2020 | 5491 | 0.110 |
Why?
|
| Female | 22 | 2024 | 391875 | 0.110 |
Why?
|
| Middle Aged | 19 | 2024 | 220382 | 0.110 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2022 | 1805 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 2 | 2023 | 9176 | 0.110 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 15820 | 0.110 |
Why?
|
| Hypersensitivity | 1 | 2022 | 1157 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2023 | 2895 | 0.100 |
Why?
|
| Prostate | 1 | 2020 | 1765 | 0.100 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2017 | 973 | 0.100 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 1942 | 0.090 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 2189 | 0.090 |
Why?
|
| Cardiomyopathies | 1 | 2023 | 1957 | 0.090 |
Why?
|
| Inflammation | 4 | 2024 | 10746 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2023 | 8611 | 0.090 |
Why?
|
| Adult | 16 | 2024 | 220781 | 0.090 |
Why?
|
| Retinal Diseases | 1 | 2016 | 704 | 0.080 |
Why?
|
| Macrophages | 2 | 2021 | 5764 | 0.080 |
Why?
|
| Phenotype | 2 | 2024 | 16585 | 0.080 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 6525 | 0.080 |
Why?
|
| Forecasting | 1 | 2016 | 2925 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2020 | 3541 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2022 | 15257 | 0.070 |
Why?
|
| Phosphoproteins | 1 | 2016 | 2444 | 0.070 |
Why?
|
| Disease Progression | 2 | 2020 | 13484 | 0.070 |
Why?
|
| Aged | 12 | 2024 | 168840 | 0.070 |
Why?
|
| Biopsy | 1 | 2017 | 6765 | 0.060 |
Why?
|
| Lung | 2 | 2022 | 9973 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 3685 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2022 | 4575 | 0.060 |
Why?
|
| Case-Control Studies | 4 | 2022 | 22097 | 0.060 |
Why?
|
| Immunoglobulin D | 1 | 2023 | 57 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 4168 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2018 | 64591 | 0.050 |
Why?
|
| Receptors, CXCR5 | 1 | 2023 | 87 | 0.050 |
Why?
|
| Salivary Glands, Minor | 1 | 2022 | 25 | 0.050 |
Why?
|
| Complement Activation | 1 | 2024 | 452 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2018 | 10425 | 0.050 |
Why?
|
| Europe | 2 | 2019 | 3419 | 0.050 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2016 | 2241 | 0.050 |
Why?
|
| Polymyalgia Rheumatica | 1 | 2022 | 53 | 0.050 |
Why?
|
| Young Adult | 3 | 2023 | 59068 | 0.050 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2022 | 121 | 0.050 |
Why?
|
| Complement System Proteins | 1 | 2024 | 788 | 0.050 |
Why?
|
| Salivary Glands | 1 | 2022 | 229 | 0.050 |
Why?
|
| Bacteroidetes | 1 | 2021 | 84 | 0.050 |
Why?
|
| Intubation | 1 | 2020 | 139 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2022 | 375 | 0.040 |
Why?
|
| Respiratory Therapy | 1 | 2020 | 125 | 0.040 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2022 | 288 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2021 | 5865 | 0.040 |
Why?
|
| Americas | 1 | 2019 | 111 | 0.040 |
Why?
|
| HLA-DR Antigens | 1 | 2020 | 631 | 0.040 |
Why?
|
| Retroperitoneal Space | 1 | 2018 | 170 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 18216 | 0.040 |
Why?
|
| Perforin | 1 | 2018 | 167 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2021 | 2468 | 0.040 |
Why?
|
| Asia | 1 | 2019 | 618 | 0.040 |
Why?
|
| Uncertainty | 1 | 2022 | 753 | 0.030 |
Why?
|
| Granzymes | 1 | 2018 | 277 | 0.030 |
Why?
|
| Species Specificity | 1 | 2021 | 2417 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2022 | 1176 | 0.030 |
Why?
|
| Aorta | 1 | 2024 | 2042 | 0.030 |
Why?
|
| Syndrome | 1 | 2022 | 3267 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2019 | 1340 | 0.030 |
Why?
|
| Behcet Syndrome | 1 | 2016 | 86 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2022 | 1301 | 0.030 |
Why?
|
| Adolescent | 3 | 2021 | 88196 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2021 | 1841 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2018 | 800 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2020 | 2642 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 3800 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2020 | 18955 | 0.030 |
Why?
|
| Neoplasms | 1 | 2022 | 22083 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2021 | 1725 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 1297 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2023 | 3088 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 58859 | 0.020 |
Why?
|
| Collagen | 1 | 2019 | 2637 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 20078 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 26063 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 81402 | 0.020 |
Why?
|
| Sex Factors | 1 | 2024 | 10538 | 0.020 |
Why?
|
| Consensus | 1 | 2019 | 3115 | 0.020 |
Why?
|
| Recurrence | 1 | 2022 | 8466 | 0.020 |
Why?
|
| Massachusetts | 1 | 2021 | 8826 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2021 | 2163 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2021 | 41366 | 0.020 |
Why?
|
| Boston | 1 | 2020 | 9326 | 0.020 |
Why?
|
| Mental Health | 1 | 2022 | 3241 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2019 | 3904 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2020 | 12320 | 0.020 |
Why?
|
| Multiple Sclerosis | 1 | 2021 | 3220 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2021 | 3759 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 168253 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 14661 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2019 | 6570 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2024 | 80430 | 0.010 |
Why?
|
| Depression | 1 | 2022 | 8104 | 0.010 |
Why?
|
| Quality of Life | 1 | 2023 | 13338 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2023 | 54339 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2021 | 42209 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2021 | 23397 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 20551 | 0.010 |
Why?
|
| Child | 1 | 2021 | 80086 | 0.010 |
Why?
|
| United States | 1 | 2019 | 72202 | 0.010 |
Why?
|
Concepts
(167)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(69)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_